Avadel Pharmaceuticals PLC (AVDL)
18.82
+0.52
(+2.84%)
USD |
NASDAQ |
May 03, 16:00
18.78
-0.04
(-0.19%)
After-Hours: 20:00
Avadel Pharmaceuticals Enterprise Value: 1.600B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 1.600B |
| May 02, 2024 | 1.553B |
| May 01, 2024 | 1.553B |
| April 30, 2024 | 1.540B |
| April 29, 2024 | 1.523B |
| April 26, 2024 | 1.508B |
| April 25, 2024 | 1.509B |
| April 24, 2024 | 1.495B |
| April 23, 2024 | 1.533B |
| April 22, 2024 | 1.462B |
| April 19, 2024 | 1.465B |
| April 18, 2024 | 1.469B |
| April 17, 2024 | 1.524B |
| April 16, 2024 | 1.533B |
| April 15, 2024 | 1.435B |
| April 12, 2024 | 1.343B |
| April 11, 2024 | 1.341B |
| April 10, 2024 | 1.358B |
| April 09, 2024 | 1.414B |
| April 08, 2024 | 1.447B |
| April 05, 2024 | 1.407B |
| April 04, 2024 | 1.398B |
| April 03, 2024 | 1.370B |
| April 02, 2024 | 1.381B |
| April 01, 2024 | 1.404B |
| Date | Value |
|---|---|
| March 28, 2024 | 1.425B |
| March 27, 2024 | 1.420B |
| March 26, 2024 | 1.366B |
| March 25, 2024 | 1.398B |
| March 22, 2024 | 1.455B |
| March 21, 2024 | 1.443B |
| March 20, 2024 | 1.396B |
| March 19, 2024 | 1.326B |
| March 18, 2024 | 1.323B |
| March 15, 2024 | 1.337B |
| March 14, 2024 | 1.353B |
| March 13, 2024 | 1.351B |
| March 12, 2024 | 1.341B |
| March 11, 2024 | 1.344B |
| March 08, 2024 | 1.376B |
| March 07, 2024 | 1.347B |
| March 06, 2024 | 1.373B |
| March 05, 2024 | 1.327B |
| March 04, 2024 | 1.356B |
| March 01, 2024 | 1.138B |
| February 29, 2024 | 1.053B |
| February 28, 2024 | 1.032B |
| February 27, 2024 | 1.101B |
| February 26, 2024 | 1.072B |
| February 23, 2024 | 1.029B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
80.76M
Minimum
May 09 2019
1.600B
Maximum
May 03 2024
517.18M
Average
412.39M
Median
Apr 07 2022
Enterprise Value Benchmarks
| Trinity Biotech PLC | 68.23M |
| Medtronic PLC | 125.48B |
| Akari Therapeutics PLC | 6.931M |
| Biophytis SA | 2.480M |
| TC BioPharm (Holdings) PLC | 1.528M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.79M |
| Revenue (Quarterly) | 19.45M |
| Total Expenses (Quarterly) | 44.35M |
| EPS Diluted (Quarterly) | -0.29 |
| Gross Profit Margin (Quarterly) | 96.44% |
| Profit Margin (Quarterly) | -148.0% |
| Earnings Yield | -10.68% |
| Normalized Earnings Yield | -9.963 |